Pfizer and Novo Holdings entered into a definitive agreement for Pfizer to acquire Novo’s portfolio company, ReViral, in a deal valued at as much as $525 million.   Founded in 2011, ReViral is a London, UK and Research Triangle Park, NC based privately held clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV).    RSV is a respiratory pathogen, which can lead to severe and li...